Insulet (NASDAQ:PODD) Stock Gets Price Target Boost from Sanford C. Bernstein

Key Points

• Sanford C. Bernstein raised Insulet’s price target to $200 from $175 and maintained an “outperform” rating, implying about 29% upside from the stock’s then-current price.
• Analyst views are mixed: MarketBeat reported an average “Hold” rating and a $189.20 consensus price target, with 13 Buy, 12 Hold and one Sell rating.
• Insulet beat quarterly expectations: EPS was $1.99 versus $1.59 forecast, while revenue of $842 million exceeded estimates and rose 19.2% year over year.

Insulet (NASDAQ:PODD - Get Free Report) had its price target increased by research analysts at Sanford C. Bernstein from $175.00 to $200.00 in a report released on Thursday, Benzinga reports. The firm currently has an "outperform" rating on the medical instruments supplier's stock. Sanford C. Bernstein's price objective would suggest a potential upside of 29.03% from the company's current price.

Several other equities research analysts have also commented on PODD. Benchmark decreased their price objective on shares of Insulet from $250.00 to $185.00 and set a "buy" rating on the stock in a research report on Thursday, August 6th. TD Cowen reaffirmed a "hold" rating on shares of Insulet in a report on Wednesday. JPMorgan Chase & Co. lowered shares of Insulet from an "overweight" rating to a "neutral" rating and lowered their price target for the company from $275.00 to $152.00 in a research report on Thursday, August 6th. BTIG Research cut shares of Insulet from a "buy" rating to a "neutral" rating in a research note on Thursday, August 6th. Finally, Wells Fargo & Company lifted their price objective on Insulet from $144.00 to $172.00 and gave the stock an "equal weight" rating in a research report on Thursday. Thirteen research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $189.20.

Insulet Price Performance

Insulet stock traded down $10.02 during mid-day trading on Thursday, reaching $155.00. The company had a trading volume of 503,801 shares, compared to its average volume of 1,394,040. Insulet has a 1 year low of $126.40 and a 1 year high of $354.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The company has a market capitalization of $10.75 billion, a P/E ratio of 28.93, a P/E/G ratio of 1.22 and a beta of 1.06. The stock's 50-day simple moving average is $141.65 and its 200-day simple moving average is $178.00.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.59 by $0.40. The company had revenue of $842.00 million during the quarter, compared to the consensus estimate of $832.63 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company's revenue for the quarter was up 19.2% on a year-over-year basis. During the same period last year, the firm earned $1.24 EPS. On average, equities analysts predict that Insulet will post 6.51 EPS for the current year.

Institutional Trading of Insulet

Several hedge funds and other institutional investors have recently bought and sold shares of the company. State of Wyoming lifted its position in shares of Insulet by 34.6% in the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier's stock valued at $60,000 after acquiring an additional 73 shares in the last quarter. American Trust grew its position in Insulet by 8.6% during the 1st quarter. American Trust now owns 1,180 shares of the medical instruments supplier's stock worth $248,000 after purchasing an additional 93 shares in the last quarter. Basecamp Wealth Advisors LLC grew its position in Insulet by 48.3% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier's stock worth $66,000 after purchasing an additional 102 shares in the last quarter. Elevation Wealth Partners LLC grew its position in Insulet by 115.6% during the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 104 shares in the last quarter. Finally, Pinnacle Associates Ltd. raised its position in Insulet by 6.1% during the third quarter. Pinnacle Associates Ltd. now owns 1,855 shares of the medical instruments supplier's stock valued at $242,000 after buying an additional 107 shares during the period.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q3 results topped expectations: Insulet reported adjusted EPS of $1.99 versus the $1.59 consensus and revenue of $842 million versus estimates of about $833 million. Revenue grew 19.2% year over year. Insulet Q3 earnings and revenues surpass estimates
• Positive Sentiment: $1 billion share buyback: The repurchase authorization may support demand for shares. Insulet also raised its 2026 outlook, although reports indicate its full-year EPS outlook was maintained. Insulet announces a $1 billion equity buyback
• Neutral Sentiment: Wells Fargo raised its target to $172 from $144 but kept an “equal weight” rating, suggesting the analyst sees some potential upside without making a bullish call. Wells Fargo raises Insulet price target
• Negative Sentiment: 2027 growth risks: The CEO expects slower growth next year and anticipates rivals will take some share from the Omnipod business. Those comments could weigh on expectations despite the strong quarter. CEO discusses slower growth and competition

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.